Elevation Oncology, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Mar 2025)

FII

7.60%

Held by 21 FIIs

DII

54.89%

Held by 20 DIIs

Promoter

25.32%

How big is Elevation Oncology, Inc.?

22-Jun-2025

As of Jun 18, Elevation Oncology, Inc. has a market capitalization of 22.61 million, with net sales of 0.00 million and a net profit of -47.99 million over the latest four quarters. The company reported shareholder's funds of 60.02 million and total assets of 95.63 million as of Dec 24.

What does Elevation Oncology, Inc. do?

22-Jun-2025

Elevation Oncology, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $14 million and a market cap of $22.61 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -95.46%.

Is Elevation Oncology, Inc. technically bullish or bearish?

20-Sep-2025

As of June 5, 2025, Elevation Oncology, Inc. is in a mildly bearish trend, with mixed technical indicators showing a bearish stance from moving averages and Dow Theory, despite some bullish signals from the MACD and RSI, and a significant underperformance compared to the S&P 500.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 22 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.06

Return on Equity

-95.46%

Price to Book

0.46

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2025)

Net Profit:

-14 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-1.88%

6 Months

-44.86%

1 Year

-85.74%

2 Years

-74.48%

3 Years

-73.36%

4 Years

-95.85%

5 Years

0.0%

Elevation Oncology, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Elevation Oncology, Inc. technically bullish or bearish?

As of 5 June 2025, the technical trend for Elevation Oncology, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators showing mixed signals. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI is bullish on a monthly basis but shows no signal weekly. However, moving averages indicate a mildly bearish trend daily, and Dow Theory confirms a bearish stance on both weekly and monthly levels. Additionally, the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -35.12% versus the S&P 500's 12.22%, and a one-year return of -85.74% compared to 17.14% for the index....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-286.06%

EBIT to Interest (avg)

-13.50

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.06

Sales to Capital Employed (avg)

Tax Ratio

0.08%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.41

EV to EBIT

0.67

EV to EBITDA

0.67

EV to Capital Employed

11.40

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

1709.39%

ROE (Latest)

-95.46%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 15 Schemes (12.2%)

Foreign Institutions

Held by 21 Foreign Institutions (7.6%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -32.71% vs 37.43% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.80",
          "val2": "-9.90",
          "chgp": "-9.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.90",
          "val2": "1.00",
          "chgp": "-10.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.40",
          "val2": "-0.90",
          "chgp": "-277.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.20",
          "val2": "-10.70",
          "chgp": "-32.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 2.63% vs 51.95% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-44.70",
          "val2": "-40.30",
          "chgp": "-10.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.00",
          "val2": "4.20",
          "chgp": "-4.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.90",
          "val2": "-5.10",
          "chgp": "82.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-44.50",
          "val2": "-45.70",
          "chgp": "2.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Mar'25

Mar'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-10.80

-9.90

-9.09%

Interest

0.90

1.00

-10.00%

Exceptional Items

-3.40

-0.90

-277.78%

Consolidate Net Profit

-14.20

-10.70

-32.71%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is -32.71% vs 37.43% in Mar 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-44.70

-40.30

-10.92%

Interest

4.00

4.20

-4.76%

Exceptional Items

-0.90

-5.10

82.35%

Consolidate Net Profit

-44.50

-45.70

2.63%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 2.63% vs 51.95% in Dec 2023

All Annual Results

Company CV

About Elevation Oncology, Inc.

Elevation Oncology, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Elevation Oncology, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Elevation Oncology, Inc.?

Watch in Real-Time

What does Elevation Oncology, Inc. do?

Is Elevation Oncology, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Elevation Oncology, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Elevation Oncology, Inc.

Company Coordinates